ABSTRACT
Changes of [Ca 2+]i were studied in peripheral blood lymphocytes of patients with ischemic heart disease and heart failure. Basal [Ca 2+]i and its changes under action of mitogenes (PHA, Con A; 10 mcg/ml), butylhydroxyquinone (BHQ; 9-14 mcM) and arachidonic acid (3-10 mc/M) were measured. Patients with heart failure had pronounced changes of kinetics and amplitude of Ca 2+ response of lymphocytes to mitogenes, significantly higher amplitudes of responses to BHQ (in patients with stage IIB and III heart failure), as well as additional increment of [Ca 2+]i in response to rachidonic acid during action of optimal concentrations of BHQ. This data allowed to propose presence of supplementary inositol triphosphate insensitive calcium depots in cells of patients with heart failure. Furthermore it was possible to assume lowering of sensitivity of Ca 2+ ATP-ase of plasmatic membranes to its natural regulators.
ABSTRACT
A clinical trial of the new antidiarrheal drug of antisecretory action fluorasol was studied with patients with salmonellosis and food toxic infections. 65 patients had moderate and 53 severe symptoms. It was established that fluorasol was superior to basic rehydration therapy in relieving diarrheal syndrome irrespective of severity of acute intestinal infections. Clinical effects on intoxication were not registered. Antidiarrheal activity of fluorasol was confirmed on the model of experimental diarrhea on isolated loops of the rat small intestine. Liquid secretion into the lumen of small intestinal isolated loops in the presence of fluorasol substance fell twofold compared to control loops.
Subject(s)
Antidiarrheals/pharmacology , Antidiarrheals/therapeutic use , Benzimidazoles/pharmacology , Benzimidazoles/therapeutic use , Diarrhea/drug therapy , Acute Disease , Adolescent , Adult , Aged , Animals , Diarrhea/etiology , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Foodborne Diseases/complications , Humans , Male , Middle Aged , Rats , Rats, WistarSubject(s)
Antidiarrheals/therapeutic use , Arachidonic Acids/antagonists & inhibitors , Cholera Toxin/toxicity , Diarrhea/drug therapy , Acetophenones/therapeutic use , Animals , Arachidonic Acid , Diarrhea/chemically induced , Disease Models, Animal , Drug Evaluation, Preclinical , In Vitro Techniques , Male , Masoprocol/therapeutic use , Rats , Rats, Inbred StrainsABSTRACT
A combined use of dibasol and furosemide was demonstrated to be followed by a decrease of furosemide toxic effect on the rat liver, an increase of its diuretic effect in patients and changes of furosemide metabolism kinetics in individuals.